This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 10
  • /
  • FDA approves Lucentis (ranibizumab injection) pref...
Drug news

FDA approves Lucentis (ranibizumab injection) prefilled syringe for age-related macular degeneration andmacular edema after RVO.- Genentech/Roche

Read time: 1 mins
Last updated:29th Jun 2017
Published:16th Oct 2016
Source: Pharmawand

Genentech, a member of the Roche Group announced that the FDA approved the Lucentis (ranibizumab injection) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is approved to treat people with wet age-related macular degeneration (AMD) and macular edema after retinal vein occlusion (RVO). The Lucentis PFS is the first syringe prefilled with an anti-VEGF medicine FDA-approved to treat two eye conditions.

The Lucentis PFS allows physicians to eliminate several steps in the preparation and administration process, including disinfecting the vial, attaching a filter needle, drawing the medicine from the vial using the needle, removing the filter needle from the syringe and replacing with an injection needle. With the Lucentis PFS, physicians attach the injection needle to the syringe and adjust the dose prior to administration.

Comment: The Lucentis 0.5 mg PFS is expected to be available in early 2017.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.